Alexion Pharmaceuticals, Inc. (ALXN)
| Market Cap | 40.15B |
| Revenue (ttm) | 6.26B |
| Net Income (ttm) | 681.80M |
| Shares Out | 220.10M |
| EPS (ttm) | 3.08 |
| PE Ratio | 58.96 |
| Forward PE | 13.81 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $181.65 |
| Previous Close | $181.99 |
| Change ($) | -0.34 |
| Change (%) | -0.19% |
| Day's Open | 181.95 |
| Day's Range | 181.21 - 182.72 |
| Day's Volume | 1,306,386 |
| 52-Week Range | 99.91 - 182.72 |
Investors seem to think that a drug from fledgling biotech Apellis Pharmaceuticals ( APLS , Financial) can go head-to-head with established treatments backed by a competitor 10 times its size.
The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.
BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
AstraZeneca PLC (LON:AZN) announced it has appointed Aradhana Sarin as an executive director and chief financial officer, effective from 1 August. The appointment is conditional on the success of the US...
Drugmaker AstraZeneca Plc said on Friday it had appointed Alexion's Aradhana Sarin as its new chief financial officer to succeed Marc Dunoyer who would be taking up a new role within the company.
EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.
AstraZeneca PLC (LON:AZN) announced it has priced €800mln (£691mln) of fixed-rate notes related to the proposed acquisition of Alexion Pharmaceuticals, Inc. They have a coupon of 0.375% maturing in 2029...
AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).
The U.K. competition regulator is mulling over AstraZeneca Plc's (NASDAQ: AZN) $39 billion takeover taker of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) over competition concern. The U.K.'s Competition a...
AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).
Britain's competition regulator said on Tuesday it was probing if AstraZeneca's $39 billion takeover of U.S. drugmaker Alexion could reduce competition for products and services in the country or elsewh...
BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021
BOSTON--(BUSINESS WIRE)--Alexion announces upcoming data presentations at the 26th European Hematology Association virtual Congress
BOSTON--(BUSINESS WIRE)--Alexion Shareholders Approve Acquisition by AstraZeneca
Elfun Trusts (Trades, Portfolio), part of Boston-based State Street Global Advisors, disclosed this week that its top five trades during the first quarter included a new position in Regions Financial Co...
Alexion (ALXN) delivered earnings and revenue surprises of 14.29% and 4.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) moved higher by 2.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 9.32% year over year to $3.52,...
BOSTON--(BUSINESS WIRE)--Alexion Reports First Quarter 2021 Results
Alexion Pharmaceuticals (NASDAQ:ALXN) unveils its next round of earnings this Friday, April 30. Here is Benzinga's everything-that-matters guide for the earnings announcement.
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financia...
Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.
Alexion Pharmaceuticals (ALXN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financia...
AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.
Alexion (ALXN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AstraZeneca PLC (LON:AZN) said its planned acquisition of rare disease specialist Alexion Pharmaceuticals Inc has been cleared by the US Federal Trade Commission. The FTSE 100 pharma giant said the appr...
Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.
Patient investors can make bank from these well-run businesses.
AstraZeneca stock jumped Tuesday after the company reaffirmed its plan to acquire Alexion Pharmaceuticals in the third quarter, even as more European countries suspended use of its Covid vaccine. The po...
NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investig...
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock?
BOSTON--(BUSINESS WIRE)--Alexion announces upcoming data presentations at the 73rd annual meeting of the American Academy of Neurology.
NEW YORK, Feb. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or...
SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Barrick Gold...
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuticals (ALXN...
ALXN vs. BMRN: Which Stock Is the Better Value Option?
Here are five of the 61 value stocks with discounted PEG.
Top Ranked Growth Stocks to Buy for February 10th
Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.
Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
BOSTON--(BUSINESS WIRE)--Alexion Reports Fourth Quarter and Full Year 2020 Results
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
About ALXN
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for ... [Read more...]
| Industry Biotechnology | IPO Date Feb 28, 1996 |
| CEO Leonard Bell | Employees 3,837 |
| Stock Exchange NASDAQ | Ticker Symbol ALXN |
Financial Performance
In 2020, ALXN's revenue was $6.07 billion, an increase of 21.61% compared to the previous year's $4.99 billion. Earnings were $603.40 million, a decrease of -74.90%.
Analyst Forecasts
According to 18 analysts, the average rating for ALXN stock is "Hold." The 12-month stock price forecast is 177.36, which is a decrease of -2.36% from the latest price.